...
首页> 外文期刊>Physics in medicine and biology. >Standardised quantitative radioiodine SPECT/CT Imaging for multicentre dosimetry trials in molecular radiotherapy
【24h】

Standardised quantitative radioiodine SPECT/CT Imaging for multicentre dosimetry trials in molecular radiotherapy

机译:用于在分子放射治疗中的多环节剂量测定试验的标准化定量放射性碘SPECT / CT成像

获取原文
获取原文并翻译 | 示例
           

摘要

The SEL-I-METRY trial (EudraCT No 2015-002269-47) is the first multicentre trial to investigate the role of I-123 and I-131 SPECT/CT-based tumour dosimetry to predict response to radioiodine therapy. Standardised dosimetry methodology is essential to provide a robust evidence-base for absorbed dose-response thresholds for molecular radiotherapy (MRT). In this paper a practical standardised protocol is used to establish the first network of centres with consistent methods of radioiodine activity quantification. Nine SPECT/CT systems at eight centres were set-up for quantitative radioiodine imaging. The dead-time of the systems was characterised for up to 2.8 GBq I-131. Volume dependent calibration factors were measured on centrally reconstructed images of I-123 and I-131 in six (0.8-196 ml) cylinders. Validation of image quantification using these calibration factors was performed on three systems, by imaging a 3D-printed phantom mimicking a patient's activity distribution. The percentage differences between the activities measured in the SPECT/CT image and those measured by the radionuclide calibrator were calculated. Additionally uncertainties on the SPECT/CT-based activities were calculated to indicate the limit on the quantitative accuracy of this method. For systems set-up to image high I-131 count rates, the count rate versus activity did not peak below 2.8 GBq and fit a non-paralysable model. The dead-times and volume-dependent calibration factors were comparable between systems of the same model and crystal thickness. Therefore a global calibration curve could be fitted to each. The errors on the validation phantom activities' were comparable to the measurement uncertainties derived from uncertainty analysis, at 10% and 16% on average for I-123 and I-131 respectively in a 5 cm sphere. In conclusion, the dead-time and calibration factors varied between centres, with different models of system. However, global calibration factors may be applied to the same system model with the same crystal thickness, to simplify set-up of future multi-centre MRT studies.
机译:SEL-I-Metry试验(Eudract No 2015-002269-47)是研究I-123和I-131 Spect / CT基肿瘤剂量测定法预测放射性碘治疗的反应的多期式试验。标准化的剂量测定方法对于提供用于分子放射疗法(MRT)的吸收剂量响应阈值的稳健循证基础是必不可少的。在本文中,使用实用的标准化方案来建立具有一致的放射性碘活性定量方法的第一中心网络。八个中心的九个SPECT / CT系统被设置为定量放射性碘成像。系统的死区时间为高达2.8 GBQ I-131。在六(0.8-196ml)汽缸中的I-123和I-131的中央重建图像上测量体积依赖性校准因子。使用这些校准因子的图像量化验证在三个系统上进行,通过对患者的活动分布进行模拟3D印刷的幻影进行。计算在SPECT / CT图像中测量的活动与通过放射性核素校准器测量的活动之间的百分比差异。另外,计算了基于SPECT / CT的活动的不确定性,以表明该方法的定量精度的限制。对于图像高I-131计数速率的系统设置,计数率与活动不低于2.8 GBQ并符合非降达的模型。死区时间和依赖体积依赖性校准因子在相同型号和晶体厚度的系统之间是可比的。因此,可以安装全球校准曲线。验证幻像活动的错误与分别在5cm球体中的I-123和I-131的平均值分析,10%和16%的测量不确定性相当。总之,居中的死区时间和校准因子在不同的系统型号之间变化。然而,全局校准因子可以应用于具有相同晶体厚度的相同系统模型,以简化未来的多中心MRT研究的设置。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号